Effect of neoadjuvant chemotherapy in patients with gastric cancer

Evaluation of neoadjuvant chemotherapy in patients with gastric cancer referred to the oncology clinic of Imam Khomeini Hospital of Ardabil

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015020220906N1

Enrollment

Registered

2015-02-15

Start date

2015-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer. Malignant neoplasm of stomach

Interventions

The regime Ajani (Taxoter 80mg / m2 - cisplatin 70mg / m2 and 5FU 750mg / M2) are used before and after chemotherapy.

Treatment - Drugs

The regime Ajani (Taxoter 80mg / m2 - cisplatin 70mg / m2 and 5FU 750mg / M2) are used before and after chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of gastric cancer; stage 2 and 3 gastric cancer; surgical patient; age 18-75 years old. Exclusion criteria: the patient's unwillingness to participate in the study; age over 75 years old; the underlying conditions; gastric cancer in stages 1 and 4; the recent history of chemotherapy or radiotherapy; performance state less than 70 Karnofsky score.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
TNM staging. Timepoint: Before and after chemotherapy. Method of measurement: TNM staging and questionnaire.	—

Secondary

Measure	Time frame
Neoadjuvant chemotherapy side effects. Timepoint: Before surgery. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Hossein Samadi

Emam Khomeini Hospital of Ardabill

dr.ah.samadi@gmail.com; ah.samadi@arums.ac.ir+98 45 3373 2883

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026